PBS update: Lenalidomide maintenance and changes to bortezomib access due to COVID19

Lenalidomide (Revlimid®) maintenance post autologous stem cell transplant We are delighted to announce that as of 1 April 2020 the pharmaceutical benefits scheme (PBS) have listed lenalidomide (Revlim...

Coronavirus and our Information & Support Groups

Our Information and Support Groups are informal gatherings for people living with myeloma, their family and friends. These meetings provide a safe space to meet other members of the myeloma community ...

ASH conference 2019

Earlier this month, a team from Myeloma Australia visited Orlando, Florida in the USA for the annual American Society of Hematology (ASH) conference as invited guests of the International Myeloma Foun...

PBAC Meeting Nov: Daratumumab combination and Pomalidomide combination

A couple of weeks ago we sent out a special advocacy edition of the Muster to inform you of the latest submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) for the upcoming November PB...

Cytogenetic testing in myeloma: The MMprofiler™

Cytogenetics is the study of chromosomes within a cell. Most commonly done at diagnosis, cytogenetic testing identifies the genetic mutations which characterise a person’s myeloma. This information he...

PBS listing changes for Pomalidomide – through the eyes of a Myeloma Support Nurse:

Just over two weeks ago, we were delighted to hear at Myeloma Australia the changes to the pharmaceutical benefit scheme (PBS) listing for Pomalidomide (Pomalyst®). Whilst the notation was slight, the...

0

American Society of Hematology Meeting 2017

A team from Myeloma Australia visited Atlanta USA in December 2017 as invited guests of the International Myeloma Foundation (IMF). This gave us the opportunity to attend the world’s biggest haematolo...

Updates from the Pharmaceutical Benefits Advisory Committee (PBAC) 22 Dec 2017

The PBAC met in November this year to review the most recent applications for new drugs or amendments to the prescribing rules for existing drugs. Four myeloma drugs were reviewed during this meeting....